SAN CARLOS, Calif.--(BUSINESS WIRE)--Rosa & Co. LLC, a Quantitative Systems Pharmacology (QSP) organization with a 15-year track record of partnering with pharmaceutical and biopharmaceutical clients, today announced the renewal of a multi-year Research Agreement with Sanofi to provide Rosa’s PhysioPD™ services.
The agreement extends Sanofi’s access to Rosa’s industry leading PhysioPD research teams in a manner that is more cost-effective and flexible than standard project-based arrangements. It increases continuity of research teams and enables deeper access to Rosa’s extensive PhysioPD-related intellectual property.
The renewal of the Sanofi PhysioPD Research Agreement extends Rosa’s global leadership in QSP, a well-documented approach to help pharma and biopharma optimize the evaluation of novel targets and compounds, guide trial designs, and inform competitive differentiation. It is also the latest evidence of the significant value that PhysioPD Research can deliver through unique scientific insights that would not be possible any other way.
"We are extremely pleased Sanofi has chosen to renew our multi-year Research Agreement. It underscores their commitment to achieve the scientific and drug development benefits of PhysioPD Research in a more systematic and long-term way,” said Founder, Chairman, & CEO Ron Beaver, PhD.
Rosa & Co was established in 2002 and has an extensive track record partnering with pharmaceutical and biopharmaceutical clients worldwide to reduce risk, optimize the use of program resources, and prioritize candidate targets. PhysioPD Research, Rosa's proprietary Quantitative Systems Pharmacology (QSP) approach, is an established scientific process that translates biology into an interactive computer simulation model representing physiology, disease, and intervention effects; a fit-for-purpose PhysioPD Research Platform.
Rosa works with client project teams to complement their work and develop a PhysioPD Research Platform of the disease of interest. The resulting resource incorporates the joint project team’s scientific interpretation of existing data and their most relevant hypotheses to address biological uncertainties.
Rosa's PhysioPD Research Platforms help optimize the evaluation of novel targets and compounds, test the effects of new combination therapies, guide study and trial designs, and inform competitive differentiation. Rosa is unique in its breadth and depth of disease area experience—metabolic, cardiovascular, and inflammatory diseases; oncology and immuno-oncology; immune dysfunctions; central nervous system disorders; dermatology; and antibacterial/antiviral biology. For more information, visit http://www.rosaandco.com.